Addiction and Pharmacology Research Laboratory (APRL) at the Research Institute
John Mendelson, MD
Dr. Mendelson is a board certified Internist who has performed human pharmacologic studies with methamphetamine, MDMA, cocaine and buprenorphine. His clinical research involves the pharmacology, physiology, and psychology of commonly abused drugs and development of treatments for drug abuse and associated medical and psychiatric complications. In his research, pharmacologically active doses of abusable drugs are studied under controlled conditions. All studies are performed at or above FDA GLP standards and his clinical research unit is equipped to ethically and safely conduct studies in licit and illicit drug users.
He has successfully conducted NIH funded studies with methamphetamine, MDMA, cocaine, methamphetamine enantiomers, marijuana, opioids, and other addictive drugs in populations that are often difficult to deal with (including untreated cocaine and heroin addicts). He has studied the cardiovascular effects of MDMA, cocaine and methamphetamine. He has performed studies on interactions between ethanol and the stimulant drugs cocaine and methamphetamine and has developed novel cocaine self-administration paradigms. He has used stable isotope methods to define the pharmacokinetics of cocaethylene formation and elimination and measure the bioavailability of intranasal methamphetamine. Dr. Mendelson performed many of the basic pharmacokinetic and abuse liability studies used to support FDA approval of Suboxone (a combination of buprenorphine and naloxone), the first new primary pharmacotherapy for opiate addiction introduced in more than 30 years. Dr. Mendelson has extensive experience working with the many regulatory bodies that oversee research with addictive drugs, including the CPMC and UCSF Institutional Review Boards, the FDA, the UCSF General Clinical Research Center, and the California Research Advisory Panel.
Click here for List of publications by J Mendelson, MD in PubMed.
Email: john.mendelson@cpmcri.org
Back to top
Gantt Galloway, Pharm D
Dr. Galloway has over 20 years of research and clinical experience with alcoholics and other addicts. He has worked in a number of treatment settings, such as the Haight-Ashbury Free Clinic. He has succeeded in designing and conducting clinical research with NIH funding in challenging clinical settings. His research interests also include genetic contributions to the development of paranoia in methamphetamine users.
Click here for list of publications by Gantt Galloway, PharmD in PubMed.
Email: Gantt@cpmcri.org
Back to top
Keith Flower, MD
Dr. Flower is a psychiatrist researching the effects of methamphetamine, cocaine, MDMA, and Salvinorin A. He is principal investigator for an NIH funded trial of sustained release naltrexone for methamphetamine dependence, and has served as co-investigator for treatments in opioid, methamphetamine, and cocaine dependence. He is interested in the integration of pharmacology and psychotherapy in drug dependence treatment, medical sequelae of drug abuse, public health policy, and what nonmedical drug use tells us about the mechanisms of mind.
Click here for a list of publications by K Flower, MD in Google Scholar.
Email: FlowerK@sutterhealth.org
Back to top
Matthew Baggott
Matthew Baggott is a PhD candidate in neuroscience at the Helen Wills Neuroscience Institute, University of California Berkeley. He is interested in the mechanisms and effects of MDMA and hallucinogens and what these pharmacological tools can tell us about the working of the brain and consciousness. His on-going research includes measuring the cognitive, social, and emotional consequences of MDMA, LSD, and methamphetamine in humans.
Email: matthew@baggott.net
Click here for List of publications by M Baggott in PubMed.
Back to top
Contact Us!
St Luke’s Hospital
San Francisco CA 94110
Open hours 8:30am-6pm
(415) 641-3370 or (415) 333- QUIT
or Email Addiction and Pharmacology
Research Laboratory (APRL)
Back to top
